Jaroszewicz Jerzy, Januszkiewicz Marcin, Flisiak Robert, Rogalska Magdalena, Kalinowska Alicja, Wierzbicka Iwona
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 Street, 15-540 Bialystok, Poland.
Cytokine. 2008 Oct;44(1):14-7. doi: 10.1016/j.cyto.2008.06.002. Epub 2008 Jul 25.
Recent studies provided in vivo evidences of an increased angiogenesis in animal model of portal hypertension and cirrhosis which was linked to increased expression of vascular endothelial growth factor. The aim of study was to evaluate the plasma concentration of VEGF and its receptors in liver cirrhosis and the possible association with the degree of liver insufficiency. Methods. Vascular endothelial growth factor (VEGF) and its soluble receptors: sVEGF-R1, sVEGF-R2 were measured in plasma of 78 patients with liver cirrhosis by ELISA. Results. The significant increase of plasma VEGF and sVEGF-R1 was observed in liver cirrhosis compared to healthy individuals (153.1+/-51.9 vs. 46.8+/-4.1pg/mL, P<0.05; 279.8+/-34.3 vs. 105.1+/-5.9pg/mL, P<0.001, respectively). Plasma VEGF and foremost sVEGF R1 showed significant associations with biochemical indices of liver function. Among clinical parameters, only ascites revealed significant association with plasma VEGR and sVEGF-R1. VEGF and sVEGF-R1 were increased respectively to the degree of liver insufficiency. It was demonstrated through a significant positive correlation with Child-Pugh score and MELD classification. In conclusion, our study suggests that serum VEGF and VEGF-R1 may reflect the hepatic function impairment in liver cirrhosis and seems to be associated with portal hypertension symptoms.
近期研究提供了门静脉高压和肝硬化动物模型中血管生成增加的体内证据，这与血管内皮生长因子表达增加有关。本研究的目的是评估肝硬化患者血浆中血管内皮生长因子（VEGF）及其受体的浓度，以及与肝功能不全程度的可能关联。方法：采用酶联免疫吸附测定法（ELISA）检测78例肝硬化患者血浆中的血管内皮生长因子（VEGF）及其可溶性受体：可溶性血管内皮生长因子受体-1（sVEGF-R1）、可溶性血管内皮生长因子受体-2（sVEGF-R2）。结果：与健康个体相比，肝硬化患者血浆VEGF和sVEGF-R1显著升高（分别为153.1±51.9 vs. 46.8±4.1pg/mL，P<0.05；279.8±34.3 vs. 105.1±5.9pg/mL，P<0.001）。血浆VEGF尤其是sVEGF R1与肝功能生化指标显著相关。在临床参数中，只有腹水与血浆VEGR和sVEGF-R1显著相关。VEGF和sVEGF-R1随肝功能不全程度增加。通过与Child-Pugh评分和终末期肝病模型（MELD）分级显著正相关得以证实。结论：我们的研究表明，血清VEGF和VEGF-R1可能反映肝硬化患者的肝功能损害，似乎与门静脉高压症状有关。
